TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02449733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV Testing
Description: Rapid HIV testing at multiple time points

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linkage to care
Description: Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linkage to care
Description: Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis (PEP)
Description: Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk-reduction counseling
Description: Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk-reduction counseling
Description: Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
Study: NCT01395420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ104
Description: IV Infusion
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox intramuscularly
Description: Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox intramuscularly
Description: Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Study: NCT02723461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile Oxytocin
Description: Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Study: NCT02649712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: Self-expandable biliary nitinol alloys stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: Self-expandable biliary nitinol alloys stent
Study: NCT01659957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Couples Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-One Couples Counseling
Study: NCT02462863

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine and fish oil
Description: Dietary supplements
Study: NCT02723461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Oxytocin
Description: Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Study: NCT00063076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targretin Gel 1%
Description: Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
Study: NCT02206035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
Study: NCT00918489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
Study: NCT01866826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subject will receive three capsules of placebo by mouth twice daily.
Study: NCT02330406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anagliptin
Description: Suiny 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Januvia 50 mg Glactiv 50 mg
Study: NCT00057642

Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline

Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine Extended Release
Study: NCT01482767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
Study: NCT00717769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN13834
Description: Low dose, orally 3 times a day (tid) for 28 days of SUN13834

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally (tid) for 28 days of SUN13834
Study: NCT02269462

Intervention type: DRUG
Intervention: Efavirenz
Description: 600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)

Intervention type: DRUG
Intervention: Efavirenz
Description: 600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)

Intervention type: DRUG
Intervention: Nevirapine
Description: 200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)

Intervention type: DRUG
Intervention: Nevirapine
Description: 200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
Study: NCT01449578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral Tablet at varying doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral Tablet at varying doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral Tablet at varying doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral Tablet at varying doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral Tablet at varying doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole Placebo
Description: Oral tablet at varying doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole Placebo
Description: Oral tablet at varying doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole Placebo
Description: Oral tablet at varying doses
Study: NCT04556942

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flow Mediated Dilation (FMD) measurement
Description: FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or \> 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Flow Mediated Dilation (FMD) measurement
Description: FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or \> 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure, pulse and blood oxygen saturation measurement
Description: Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood pressure, pulse and blood oxygen saturation measurement
Description: Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient.
Study: NCT01449578

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole Placebo
Description: Oral tablet at varying doses
Study: NCT04556942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ST George Respiratory Questionnaire
Description: The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
Study: NCT00835302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervicothoracic manipulation
Description: Thrust and non-thrust manipulation to the cervical and thoracic spine
Study: NCT02936024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-Stage GSLO Technique
Description: The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: One-Stage GSLO Technique
Description: The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
Study: NCT04625439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality Feedback Self-Management Intervention
Description: The intervention is a personality feedback report that will tell participants whether they scored low (bottom third), average (middle third), or high (top third) on each of the five factor personality characteristics based on gender-matched norms. In addition to a description of general tendencies based on their level of each personality trait, the feedback will include information about how scoring in a given category may relate to an individual's cancer self-management or healthcare decision making. The feedback for each personality trait will include recommendations for how to improve key outcomes.
Study: NCT01342588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electric pulse train stimulation
Description: Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
Study: NCT04556942

Intervention type: OTHER
Group type: OTHER
Intervention: ST George Respiratory Questionnaire
Description: The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity level (PAL) measurement
Description: PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
Study: NCT04289961

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Portal vein sampling
Description: During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
Study: NCT04556942

Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity level (PAL) measurement
Description: PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Withdrawal of a blood sample
Description: 5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Withdrawal of a blood sample
Description: 5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Bronchoscopic Lung Volume Reduction
Description: Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
Study: NCT01302028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral
Study: NCT01080846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 600 mcg of sublingual misoprostol
Study: NCT02994875

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT00413790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin tablets 15 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Tolterodine extended release (ER) 4 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study: NCT00697372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus eluting stent
Description: Implantation of Sirolimus eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: Implantation of Everolimus eluting stent
Study: NCT01877213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching with coordinate care
Description: The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
Study: NCT01382238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg tablet
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg oral granules
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
Study: NCT01519856

Intervention type: DRUG
Intervention: piribedil (Clarium)
Description: oral tablets, 50 mg
Study: NCT01737567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Narrow Band Imaging.
Description: Using Bright Narrow Band Imaging to detect colonic adenomas.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Light Endoscopy
Description: Use of White Light Endoscopy to detect colonic adenomas.
Study: NCT01865825

Intervention type: RADIATION
Intervention: Esophageal Barium Xray
Description: •Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day.
Study: NCT04035304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Coach
Description: Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises.
Study: NCT04556942

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed Bronchoscopic Lung Volume Reduction
Description: Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
Study: NCT00629135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Description: Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Description: Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
Study: NCT01711073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobilization with G-CSF and Mozobil
Description: Treatment with drugs for mobilization of MSCs
Study: NCT03705858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ac-Lintuzumab
Description: 225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
Study: NCT04585191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Aid
Description: Intervention is a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? that patients receive prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Educational Handout
Description: Attention control is an existing health education handout that provides some general health advice geared towards older patients.
Study: NCT04129879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ABC technique
Description: The intraperitoneal use of methylene blue diluted isotonic sodium chloride solution to visualize endometriotic lesions